Zacks Investment Research lowered shares of Checkpoint Therapeutics (NASDAQ:CKPT) from a hold rating to a sell rating in a research report released on Wednesday.

According to Zacks, “Checkpoint Therapeutics, Inc. is a clinical stage, immuno oncology biopharmaceutical. It focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Checkpoint Therapeutics, Inc. is headquartered in New York City. “

Several other equities research analysts have also recently commented on CKPT. ValuEngine upgraded Checkpoint Therapeutics from a hold rating to a buy rating in a research note on Thursday, November 1st. HC Wainwright set a $11.00 price target on Checkpoint Therapeutics and gave the stock a buy rating in a research note on Friday, November 2nd.

NASDAQ CKPT traded up $0.21 on Wednesday, reaching $2.51. The stock had a trading volume of 103,008 shares, compared to its average volume of 45,591. Checkpoint Therapeutics has a 12-month low of $1.89 and a 12-month high of $6.50. The stock has a market cap of $69.03 million, a P/E ratio of -2.51 and a beta of 1.98.

Checkpoint Therapeutics (NASDAQ:CKPT) last issued its quarterly earnings data on Friday, November 2nd. The company reported ($0.32) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.26) by ($0.06). Checkpoint Therapeutics had a negative net margin of 3,800.00% and a negative return on equity of 139.01%. The firm had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.26 million. Equities analysts predict that Checkpoint Therapeutics will post -1.1 EPS for the current year.

Institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in shares of Checkpoint Therapeutics during the second quarter worth approximately $164,000. Millennium Management LLC purchased a new stake in shares of Checkpoint Therapeutics during the first quarter worth approximately $331,000. Finally, Bainco International Investors purchased a new stake in shares of Checkpoint Therapeutics during the second quarter worth approximately $277,000. Institutional investors and hedge funds own 1.84% of the company’s stock.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's products include CK-301 in Phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC); and CK-101 in the Phase 1 portion of a Phase 1/2 clinical trial for the treatment of epidermal growth factor receptor (EGFR) mutation-positive NSCLC.

Featured Article: How Do You Calculate Return on Investment (ROI)?

Get a free copy of the Zacks research report on Checkpoint Therapeutics (CKPT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Checkpoint Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkpoint Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.